EP4702014A1 - Composés bifonctionnels pour dégrader le braf par l'intermédiaire d'une voie ubiquitine-protéosome - Google Patents

Composés bifonctionnels pour dégrader le braf par l'intermédiaire d'une voie ubiquitine-protéosome

Info

Publication number
EP4702014A1
EP4702014A1 EP24730823.2A EP24730823A EP4702014A1 EP 4702014 A1 EP4702014 A1 EP 4702014A1 EP 24730823 A EP24730823 A EP 24730823A EP 4702014 A1 EP4702014 A1 EP 4702014A1
Authority
EP
European Patent Office
Prior art keywords
fluorophenyl
piperidin
sulfonamide
pyridin
dioxopiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24730823.2A
Other languages
German (de)
English (en)
Inventor
Ge Peng
Jeffrey Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nurix Therapeutics Inc
Original Assignee
Nurix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc filed Critical Nurix Therapeutics Inc
Publication of EP4702014A1 publication Critical patent/EP4702014A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des composés de formule (I) utiles pour la dégradation ex vivo, in vitro ou in vivo de BRAF par l'intermédiaire d'une voie protéolytique de l'ubiquitine. La présente invention concerne également des compositions pharmaceutiquement acceptables comprenant lesdits composés, ainsi que des procédés d'utilisation des compositions dans le traitement de maladies, d'affections et/ou de troubles divers. (I)
EP24730823.2A 2023-04-28 2024-04-26 Composés bifonctionnels pour dégrader le braf par l'intermédiaire d'une voie ubiquitine-protéosome Pending EP4702014A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363462918P 2023-04-28 2023-04-28
PCT/US2024/026679 WO2024227104A1 (fr) 2023-04-28 2024-04-26 Composés bifonctionnels pour dégrader le braf par l'intermédiaire d'une voie ubiquitine-protéosome

Publications (1)

Publication Number Publication Date
EP4702014A1 true EP4702014A1 (fr) 2026-03-04

Family

ID=91376068

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24730823.2A Pending EP4702014A1 (fr) 2023-04-28 2024-04-26 Composés bifonctionnels pour dégrader le braf par l'intermédiaire d'une voie ubiquitine-protéosome

Country Status (8)

Country Link
EP (1) EP4702014A1 (fr)
JP (1) JP2026517764A (fr)
KR (1) KR20260005915A (fr)
CN (1) CN121548574A (fr)
AU (1) AU2024260700A1 (fr)
IL (1) IL323616A (fr)
MX (1) MX2025012819A (fr)
WO (1) WO2024227104A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3867242A1 (fr) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome
EP3924350A1 (fr) 2019-02-13 2021-12-22 Nurix Therapeutics, Inc. Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome
CA3160713A1 (fr) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Composes bifonctionnels pour la degradation de la btk par l'intermediaire de la voie de l'ubiquitine-proteosome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112812109B (zh) * 2019-11-18 2022-06-21 中国科学院微生物研究所 化合物DaP-01及其制备方法和应用
EP4232023A4 (fr) * 2020-10-26 2025-11-12 Dana Farber Cancer Inst Inc Composés pour la dégradation ciblée de protéines de kinases
MX2023012981A (es) * 2021-05-03 2024-01-11 Nurix Therapeutics Inc Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.

Also Published As

Publication number Publication date
AU2024260700A1 (en) 2025-11-13
KR20260005915A (ko) 2026-01-12
MX2025012819A (es) 2025-12-01
CN121548574A (zh) 2026-02-17
IL323616A (en) 2025-11-01
JP2026517764A (ja) 2026-06-02
WO2024227104A1 (fr) 2024-10-31

Similar Documents

Publication Publication Date Title
JP7741282B2 (ja) ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
JP7687970B2 (ja) Ｉｒａｋ分解剤およびその使用
EP4334302A1 (fr) Composés pour inhiber ou dégrader des protéines cibles, compositions les comprenant, leurs procédés de fabrication et leurs procédés d'utilisation
AU2022349569A1 (en) Pyridine derivative and use thereof
KR20230143632A (ko) Irak 분해제 및 이의 용도
KR20220112273A (ko) 유비퀴틴 프로테오솜 경로를 통해 btk를 분해하기 위한 이작용성 화합물
AU2024260700A1 (en) Bifunctional compounds for degrading braf via ubiquitin proteosome pathway
US20240279202A1 (en) Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
TW201919640A (zh) 作為ｒｓｖ抑制劑的組合藥劑
CN107108561A (zh) 用作irak抑制剂的杂芳基化合物及其用途
EP2809652B1 (fr) Dérivés d'isoquinoléine et de naphtyridine
CA3078579A1 (fr) Composes inhibiteurs de pyrimidine tbk/ikk.epsilon. et leurs utilisations
CA3235182A1 (fr) Composes bifonctionnels pour la degradation de l'itk par l'intermediaire d'une voie de l'ubiquitine proteosome
OA21863A (en) Indazole based compounds and associated methods of use.
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
HK1242303B (en) Heteroaryl compounds as irak inhibitors and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)